Inmedix® to present its new FDA-cleared CloudHRV system at the 2nd Annual Point-of-Care Testing USA 2025 conference.

Inmedix CloudHRV System

CEO Andrew J. Holman MD to discuss the power of precision heart rate variability (HRV)

NORMANDY PARK, WA, UNITED STATES, December 3, 2025 /EINPresswire.com/ -- Inmedix^®, Inc. (“Inmedix”) CEO, rheumatologist and co-founder Andrew J. Holman MD, will be speaking at the 2nd Annual Point-of-Care Testing USA 2025 conference in Cambridge, MA on Monday, December 8. He will share the advantages of precision heart rate variability (HRV) testing in the clinic with the recently FDA-cleared Inmedix CloudHRV^® System.

Medical grade, FDA-cleared HRV provides indirect measures of the sympathetic (fight-or-flight) and parasympathetic (rest/restorative) components of the human autonomic nervous system (ANS). A precision electrocardiogram (ECG) is required to identify each heartbeat and to measure the precise timing between beats. These ECG measurements of heart rate (pulse) variability over time reflect how the ANS influences cardiac rhythm during respiration. Subsequently, mathematical formulae can be applied to render HRV indices of sympathetic and parasympathetic activity.

The Inmedix CloudHRV System is the first device cleared by the FDA as a cloud HRV diagnostic calculated from a high-fidelity ECG which also includes Baevsky indices of parasympathetic and sympathetic activity. It represents a milestone in modern HRV assessment with scalability, precision and affordability for patients and clinicians in the clinical setting.

Inmedix CloudHRV provides comprehensive HRV at rest with medical precision in the clinic setting in just 5 minutes. Application of CloudHRV as a reimbursed tool for patient care is determined exclusively by the clinician and the CloudHRV ECG display is contraindicated for use to monitor or diagnose cardiovascular disease.

“Stress biology, controlled by the autonomic nervous system, is intuitive and frustrating to both patients and clinicians,” said Dr. Holman. “Unfortunately, quantifying it with clinical precision has been lacking. Now, FDA-cleared and reimbursed precision heart rate variability can provide the insight clinicians and patients seek and need. This advance offers the potential to quantify the biochemistry of stress and to evaluate myriad approaches to mitigating it with scientific scrutiny.”

“The ANS is the command-and-control center within our brain impacting nearly every clinical aspect of healthcare. It often plays a role in why patients respond differently to the same treatment. No longer can we or should we guess why or how this ever-present biology impacts disease onset, treatment efficacy and even prevention. As a clinician, being able to quantify ANS state with FDA-cleared, precision HRV appears to be an exciting opportunity to address unmet healthcare needs.”

About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.
Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd., are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress modulated within the brain by the autonomic nervous system (ANS). Its CloudHRV System is FDA cleared to provide 1996 international standard time and frequency domain HRV as well as geometric domain HRV indices non-invasively in 5 minutes in the clinic setting.

NOTICE:
This Press Release contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies, effectiveness of its research, product capabilities and the market’s demand for its respective products. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing, regulatory approval, developments in raw material, personnel costs, sales as well as legislative, fiscal, and other regulatory measures. Any forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.

Andrew J Holman MD
Inmedix Inc.
+1 206-466-3349
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.